Sun Pharmaceutical Industries (SUNPHARMA) Fundamentals 2026 — P/E 40.6x, Revenue Analysis | SniperIQ
Sun Pharmaceutical Industries (SUNPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹4.66 Lakh Crore, trading at ₹1942.95 on the BSE. This SniperIQ fundamentals page covers Sun Pharmaceutical Industries's valuation (P/E 40.6x, P/B 5.6x), profitability (net margin 19.6%), revenue (₹58,462 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sun Pharmaceutical Industries's market cap?
Sun Pharmaceutical Industries (SUNPHARMA) has a market capitalization of approximately ₹4.66 Lakh Crore, trading at ₹1942.95 on the BSE. Market cap moves with the live share price.
What is Sun Pharmaceutical Industries's P/E ratio?
Sun Pharmaceutical Industries's trailing twelve-month P/E ratio is 40.6x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries runs a net profit margin of 19.6%, a gross margin of 55.7%, and an operating margin of 23.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sun Pharmaceutical Industries generate?
Sun Pharmaceutical Industries reported revenue of ₹58,462 Crore for fiscal year 2026, with net income of ₹11,479 Crore and earnings per share (EPS) of 47.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sun Pharmaceutical Industries pay a dividend?
Sun Pharmaceutical Industries offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sun Pharmaceutical Industries financially healthy?
Sun Pharmaceutical Industries carries a debt-to-equity ratio of 0.06x and a current ratio of 2.82x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sun Pharmaceutical Industries a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sun Pharmaceutical Industries (SUNPHARMA) the key facts are: market cap ₹4.66 Lakh Crore, P/E 40.6x, revenue ₹58,462 Crore, 52-week range 1547.25-1951.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sun Pharmaceutical Industries's full fundamentals live
Get Sun Pharmaceutical Industries's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.